Contemporary Use of Guideline-Directed Medical Therapy in US Adults with Advanced CKD and High Risk of Cardiovascular Events

“Low use of guideline-directed medical therapy (GDMT) in advanced chronic kidney disease (CKD) points to a similar system-level gap. In advanced CKD, nephrology should lead. We manage potassium and eGFR changes and are best positioned to keep patients on therapy through the expected early eGFR dip.”

“your analysis of more than 106,000 adults with advanced CKD found that SGLT2 inhibitor use ranged from 11% to 17% and renin-angiotensin system inhibitor use from 35% to 39%, even though the risk of cardiovascular events exceeded the risk of kidney failure.”